Department of Child Health, Dr. Cipto Mangunkusumo National Central Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
J Trop Pediatr. 2022 Apr 5;68(3). doi: 10.1093/tropej/fmac025.
While the number of cases of multisystem inflammatory syndrome in children (MIS-C) is increasing, reported cases in Asian countries are still low, particularly in Indonesia. This study aimed to describe the characteristics of patients with MIS-C in a tertiary referral hospital in Indonesia.
This is a cross-sectional study with collected data of patients with MIS-C admitted to Dr. Cipto Mangunkusumo from March 2020 to April 2021.
The first case of MIS-C was detected 5 months after the first reported coronavirus disease 2019 case in Indonesia. Thirteen patients out of 158 positive admitted patients for COVID-19 were diagnosed with MIS-C during the study period. Of these 13 patients, 2 patients (15%) had a fatal outcome. Subjects were predominantly male, and the median age was 7.58 years (IQR 12.3) years. Most patients required mechanical ventilation (7 out of 13 patients) and intubation (8 out of 13 patients). Patients who needed intubation usually needed mechanical ventilation. All inflammatory markers, white blood cells, neutrophil counts, and all coagulation factor parameters (except for normal prothrombin time and activated partial prothrombin time) were elevated. The median time to MIS-C diagnosis was 2 days in the survivor group (n = 11) compared to 8.5 days in the non-survivor group (n = 2). Compared to the non-survivor group, those who survived spent more days in the hospital, received vasopressors earlier, and did not require mechanical ventilation as early as the non-survivors.
Our work highlights the differences in MIS-C clinical course, treatment, and clinical outcomes between the two groups.
虽然儿童多系统炎症综合征 (MIS-C) 的病例数正在增加,但亚洲国家报告的病例仍然较少,印度尼西亚尤其如此。本研究旨在描述印度尼西亚一家三级转诊医院 MIS-C 患者的特征。
这是一项横断面研究,收集了 2020 年 3 月至 2021 年 4 月期间在 Dr. Cipto Mangunkusumo 医院住院的 MIS-C 患者的数据。
印度尼西亚首例 COVID-19 病例报告后 5 个月发现首例 MIS-C 病例。在研究期间,158 例 COVID-19 阳性住院患者中有 13 例被诊断为 MIS-C。这 13 例患者中有 2 例(15%)死亡。患者主要为男性,中位年龄为 7.58 岁(IQR 12.3)岁。大多数患者需要机械通气(13 例中有 7 例)和插管(13 例中有 8 例)。需要插管的患者通常需要机械通气。所有炎症标志物、白细胞、中性粒细胞计数和所有凝血因子参数(除正常凝血酶原时间和活化部分凝血酶原时间外)均升高。在幸存者组(n = 11),MIS-C 诊断的中位时间为 2 天,而非幸存者组(n = 2)为 8.5 天。与非幸存者组相比,幸存者在医院的住院时间更长,更早使用血管加压药,且不需要机械通气的时间早于非幸存者。
我们的工作强调了两组 MIS-C 临床病程、治疗和临床结局的差异。